Applications are invited for the following job positions in several new R&D Centres located at the Hong Kong Science Park:
Centre for Eye and Vision Research Limited
Centre for Eye and Vision Research Limited (CEVR) is a research collaboration between The Hong Kong Polytechnic University (PolyU) and the University of Waterloo (UW) in Canada. It will be located at the Hong Kong Science Park, New Territories, Hong Kong. It will be the first global hub performing ground-breaking research in five key areas – myopia and eye growth, ocular drug discovery and delivery, vision enhancement, tear film and ocular surface and advanced optometric technology. The mission of CEVR is to generate technologies to prevent vision loss in the aging population and preserve healthy vision.
Centre for Immunology & Infection Limited
The LKS Faculty of Medicine of the University of Hong Kong (HKUMed) and the Institut Pasteur are combining their considerable expertise to establish the Centre for Immunology & Infection (C2I), a major initiative that adopts innovative strategies to identify and contain emerging infectious diseases, and transform Hong Kong and the Greater Bay Area into a global hub of knowledge and research in this field. The C2I aims to characterise immune responses to infectious agents and their components in a healthy Asian population and develop new vaccine platforms for influenza, new strategies for mosquito-borne viruses and new treatments for lethal respiratory virus infections.
Centre for Oncology and Immunology Limited
For over a century, scientists and clinicians have collectively combatted cancer using a diversity of approaches, including drug treatment, surgery, radiation and chemotherapy. In spite of the advances in prognosis and therapeutics in different types of cancer, many malignancies including liver, gastric, colorectal, head/neck, breast, ovarian and lung cancers remain difficult to treat. The long-term objective of the Centre for Oncology and Immunology is to employ novel functional screens, animal and cell models including organoids, immune-oncology approach, as well as advanced genomic and proteomic techniques down to single cell resolution to identify novel “druggable” cancer targets for hard-to-treat malignancies. The ultimate goal is to develop therapeutics against these targets and to conduct clinical trials evaluating these drugs along with biomarkers with an eye to their eventual commercialization worldwide. Success in this venture will address pressing unmet medical needs and establish Hong Kong as a leading hub of innovative anti-cancer and immuno-oncology drug development.
Centre for Translational Stem Cell Biology Limited
Groundbreaking stem cell technology developed by HKUMed scholar underpins the Centre for Translational Stem Cell Biology, which investigates applications in stem cell and regenerative medicine, organ transplantation, genomic medicine, and therapeutic product development.
The outputs from the Centre are expected to provide enormous economic and commercial benefits to Hong Kong through the new technologies and lines of research created and the products that will be built on that. This project will also contribute to Hong Kong’s transformation into a global innovative hub.
Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences Limited
Laboratory of Data Discovery for Health Limited
As innovation continues to flourish in the area of healthcare technology, there is a vacant niche for the careful and proper curation of data resources in order to bridge the gap in developing novel, deep analytics that can stand up to scientific scrutiny. The nascent Laboratory of Data Discovery for Health (D24H) is set to fill this gap. It aims to gather and curate massive, unique data resources and to develop new, deep, frontier analytics in protecting global public health and improving individual healthcare through precision medicine. The D24H is a research institute based in Hong Kong owned by The University of Hong Kong (HKU).
Laboratory for Synthetic Chemistry and Chemical Biology Limited
Established as a research unit in Hong Kong Science Park and led by Prof. Chi-Ming Che, the Laboratory integrates chemical science and biomedical science for the development of new molecular medicines and diagnostics tools for the treatment and analysis of human diseases with a focus on cancer.